87 related articles for article (PubMed ID: 25907246)
1. Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice.
Xuan W; Yan Y; Wan M; Wu X; Ji D; Wang L; Lin C; Chen Y; Yu Y; Zhang X
Int Immunopharmacol; 2015 Jul; 27(1):95-103. PubMed ID: 25907246
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic potency of HSP65-GTL in GL261 glioma-bearing mice.
Yan Y; Fang M; Xuan W; Wu X; Meng X; Wang L; Yu Y
J Immunother; 2015; 38(9):341-9. PubMed ID: 26448578
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice.
Dong B; Sun L; Wu X; Zhang P; Wang L; Wei H; Zhou L; Hu X; Yu Y; Hua S; Wang L
Cancer Immunol Immunother; 2010 Jun; 59(6):899-908. PubMed ID: 20087582
[TBL] [Abstract][Full Text] [Related]
4. [Effect of MHSP65-TCL anti-melanoma vaccine on the activity of immunocytes].
Dong B; Dai G; Qi Z; Yang G; Lu J; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Nov; 33(11):1673-7. PubMed ID: 24273276
[TBL] [Abstract][Full Text] [Related]
5. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with FasL-/TCL plus MHSP65 induces improved anti-lung cancer immunity in mice.
Dong B; Dai G; Ding Y; Wang B; Zhang S
Int Immunopharmacol; 2018 Feb; 55():306-311. PubMed ID: 29310106
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
8. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response.
Rossowska J; Anger N; Kicielińska J; Pajtasz-Piasecka E; Bielawska-Pohl A; Wojas-Turek J; Duś D
Immunobiology; 2015 Mar; 220(3):389-98. PubMed ID: 25454807
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
[TBL] [Abstract][Full Text] [Related]
11. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma.
Guo QY; Yuan M; Peng J; Cui XM; Song G; Sui X; Lu SB
J Exp Clin Cancer Res; 2011 Feb; 30(1):24. PubMed ID: 21352555
[TBL] [Abstract][Full Text] [Related]
13. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
15. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
[TBL] [Abstract][Full Text] [Related]
16. Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate.
Ito A; Fujioka M; Tanaka K; Kobayashi T; Honda H
J Biosci Bioeng; 2005 Jul; 100(1):36-42. PubMed ID: 16233848
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer.
Kim HS; Choo YS; Koo T; Bang S; Oh TY; Wen J; Song SY
Immunol Lett; 2006 Mar; 103(2):142-8. PubMed ID: 16313973
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
19. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model.
Fuentes D; Avellanet J; Garcia A; Iglesias N; Gabri MR; Alonso DF; Vazquez AM; Perez R; Montero E
Breast Cancer Res Treat; 2010 Apr; 120(2):379-89. PubMed ID: 19377876
[TBL] [Abstract][Full Text] [Related]
20. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
